What is Bitterroot Bio?
Bitterroot Bio, based in Palo Alto, is a biotechnology company dedicated to developing innovative immunotherapies targeting cardiovascular disease. The company's focus on this critical area of unmet medical need positions it within a rapidly evolving sector of healthcare innovation. The recent Series A financing round, characterized as a major enterprise-level funding, underscores the significant potential investors see in Bitterroot Bio's scientific approach and therapeutic pipeline.
How much funding has Bitterroot Bio raised?
Bitterroot Bio has raised a total of $145M across 1 funding round:
Series A
$145M
Series A (2023): $145M with participation from Alt Disrupt, ARCH Venture Partners, and Deerfield
Key Investors in Bitterroot Bio
Alt Disrupt
Koch Disruptive Technologies (KDT) empowers principled entrepreneurs by providing flexible capital solutions and access to a diverse ecosystem of experts and commercial partners. The company focuses on accelerating innovation and commercialization of transformative technologies to drive positive change.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
What's next for Bitterroot Bio?
The substantial capital infusion from this major strategic investment is expected to fuel Bitterroot Bio's research and development efforts, potentially accelerating the progression of its lead candidates through clinical trials and towards commercialization. This funding will likely enable the company to expand its scientific team, enhance its operational capabilities, and further solidify its position in the competitive biotechnology landscape. The company's trajectory suggests a focus on scaling its operations and advancing its platform for broader therapeutic applications.
See full Bitterroot Bio company page
